984-47-4: Medroxyprogesterone EP Impurity A

It is one of impurity present in Medroxyprogesterone, Medroxyprogesterone acetate inhibits the production of gonadotropin, preventing follicular maturation and ovulation, which is responsible for its ability to prevent pregnancy. This action also thins the endometrium. MPA reduces nuclear estrogen receptors and DNA synthesis in epithelial cells of the endometrium, also induces p53 dependant apoptosis in certain cancer cell lines, and inhibits GABA-A receptors, which reduces nuclear estrogen receptors and DNA synthesis in epithelial cells of the endometrium and induces p53 dependant apoptosis in cancer cell lines, Medroxyprogesterone Acetate used as a contraceptive and in the treatment of secondary amenorrhea, abnormal uterine bleeding.

Additional information on CAS 984-47-4

Catalogue No.

VE007815

CAS No.

984-47-4

Molecular Formula

C24H34O5

Molecular Weight

402.54 g/mol

Parent drug

Medroxyprogesterone

IUPAC Name

(6R, 8R, 9S, 10R, 13S, 14S, 17R)-17-acetyl-6-hydroxy-6, 10, 13-trimethyl-3-oxo-2, 3, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate

Synonyms

N/A

References

Piccinni, M.-P., Lombardelli, L., Logiodice, F., Kullolli, O., Maggi, E., & Barkley, M. S. (2019). Medroxyprogesterone Acetate Decreases Th1, Th17, and Increases Th22 Responses via AHR Signaling Which Could Affect Susceptibility to Infections and Inflammatory Disease. Frontiers in Immunology, 10. https://doi.org/10.3389/fimmu.2019.00642

Status

In-stock